BOC-GROUP
15.1.2020 15:29:10 CET | Business Wire | Press release
BOC Group , a global leader in enterprise business process analysis software (EBPA), and TIM Solutions , a leading provider of business process management (BPM) software for low-code human workflow automation, announced their strategic partnership today, focused on delivering accelerated digitalization of Business Process Automation at the enterprise level.
Both BOC Group and TIM have experienced that rapid automation of an existing manual process is the key first step in successful delivery of process automation. Once the automation is up-and-running, process analysis and design ensure that the process is quickly optimized further to reach cost reduction efficiencies of up-to 80%. What’s more, this approach delivers on all key targets of automation – reduction of redundant process activities, digitalization of manual tasks, and the overall improvement of customer experience. By combining TIM’s process automation with ADONIS’ process design and analysis capabilities, organizations can expect both a shorter time-to-value when automating processes, and a higher value-add delivered by the optimally designed automation.
The past months of collaboration between TIM and BOC Group have culminated today in a meeting of both management teams at BOC Group’s headquarters in Vienna, Austria, where the release of the ADONIS Process Automation module on the BOC Marketplace was announced. Customers of both partners can now benefit from this native integration that combines the intuitive process design, analysis and simulation of ADONIS with the seamless deployment, automation and monitoring of business processes in TIM’s process automation platform.
“Our customers seek to use low-code process automation as a key step in their digital journey. TIM is uniquely positioned as a simple, powerful and cost-effective automation platform that allows our customers to turn their process designs into automated workflows” mentioned Dr. Harald Kühn, BOC Group Board member. “We are excited about ADONIS Process Automation, powered by TIM, going live today on the BOC Marketplace” added Dr. Kühn.
“Having an optimal process design is a key success factor in rolling-out an automated human workflow. We are certain that the process analysis and design capabilities of ADONIS will be greatly beneficial when designing and optimizing automated workflows.” said TIM Solutions CEO, Mr. Hermann Filss “We are excited to be partnering with BOC Group as we look to directly profit from their global client footprint and rapidly spread the use of TIM around the world,” added Mr. Filss.
Both vendors have kicked-off campaigns to roll-out the integration as they look to capture a very active process automation market with their unique combined offering. Interested parties are welcome to schedule a Proof of Concept through the BOC Marketplace .
About BOC Group
BOC is a global leader in Enterprise Modelling Software across the Enterprise Business Process Analysis (EBPA), Governance Risk and Compliance (GRC) and Enterprise Architecture (EA) domains. Enabling customers to successfully and continuously re-design their digital enterprise to ensure business success at every level of the organization.
ADONIS customers include:
- Allianz
- Comcast
- Emerson
- Hilti
- Telefonica
BOC delivers products and services globally to over 1,000 companies supported by over 90 partners around the globe.
About TIM Solutions
TIM Solutions is focused on developing a simple method for automating and managing human workflows. They provide comprehensive solutions and consulting to their customers in the field Business Process Automation and Business Process Management.
TIM customers include:
- BMW AG
- Deutsche Bahn AG
- ManpowerGroup
- E.ON SE
- Tata Consultancy Services
TIM BPM Suite is used by more than 310 companies in 56 countries around the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200115005507/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom